Check-Cap Ltd. (CHEK) Reaches $4.54 After 5.00% Down Move; Achillion Pharmaceuticals (ACHN) SI Decreased By 10.57%

May 23, 2018 - By Dolores Ford

Check-Cap Ltd. (NASDAQ:CHEK) Logo

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) had a decrease of 10.57% in short interest. ACHN’s SI was 9.23 million shares in May as released by FINRA. Its down 10.57% from 10.32 million shares previously. With 1.87 million avg volume, 5 days are for Achillion Pharmaceuticals Inc (NASDAQ:ACHN)’s short sellers to cover ACHN’s short positions. The SI to Achillion Pharmaceuticals Inc’s float is 9.01%. The stock decreased 0.23% or $0.009 during the last trading session, reaching $3.721. About 194,937 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since May 23, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

The stock of Check-Cap Ltd. (NASDAQ:CHEK) is a huge mover today! The stock decreased 2.37% or $0.11 during the last trading session, reaching $4.54. About 409,342 shares traded. Check-Cap Ltd. (NASDAQ:CHEK) has declined 76.56% since May 23, 2017 and is downtrending. It has underperformed by 88.11% the S&P500.The move comes after 5 months negative chart setup for the $24.02M company. It was reported on May, 23 by Barchart.com. We have $4.31 PT which if reached, will make NASDAQ:CHEK worth $1.20 million less.

Among 4 analysts covering Check-Cap (NASDAQ:CHEK), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Check-Cap had 13 analyst reports since July 22, 2015 according to SRatingsIntel. On Friday, May 20 the stock rating was maintained by Chardan Capital Markets with “Buy”. On Tuesday, November 28 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Thursday, September 28. The firm has “Buy” rating given on Tuesday, March 13 by H.C. Wainwright. The stock has “Buy” rating by Chardan Capital Markets on Wednesday, March 16. The stock of Check-Cap Ltd. (NASDAQ:CHEK) earned “Buy” rating by H.C. Wainwright on Wednesday, May 23. The company was maintained on Wednesday, July 22 by Chardan Capital Markets. The firm earned “Buy” rating on Tuesday, January 19 by Maxim Group. The stock of Check-Cap Ltd. (NASDAQ:CHEK) earned “Buy” rating by Rodman & Renshaw on Thursday, January 19. H.C. Wainwright maintained Check-Cap Ltd. (NASDAQ:CHEK) rating on Friday, August 11. H.C. Wainwright has “Buy” rating and $600 target.

More notable recent Check-Cap Ltd. (NASDAQ:CHEK) news were published by: Seekingalpha.com which released: “Check-Cap up 14% premarket on positive study data” on May 22, 2018, also Seekingalpha.com with their article: “Check-Cap up 13% on Q1 result” published on May 17, 2018, Benzinga.com published: “8 Biggest Price Target Changes For Wednesday” on May 23, 2018. More interesting news about Check-Cap Ltd. (NASDAQ:CHEK) were released by: Benzinga.com and their article: “What’s Going On With Check Cap?” published on April 25, 2018 as well as Globes.Co.Il‘s news article titled: “Check-Cap plunges after raising $17.5m in Nasdaq offering” with publication date: May 06, 2018.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. The company has market cap of $24.02 million. The Company’s C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. It currently has negative earnings.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $514.82 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Among 12 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Achillion Pharma had 28 analyst reports since August 13, 2015 according to SRatingsIntel. FBR Capital initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Thursday, September 15 with “Outperform” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by FBR Capital on Wednesday, February 7. Jefferies initiated it with “Hold” rating and $8 target in Wednesday, September 9 report. The rating was initiated by Chardan Capital Markets on Thursday, July 14 with “Sell”. Leerink Swann maintained the shares of ACHN in report on Wednesday, May 4 with “Market Perform” rating. The rating was upgraded by UBS on Tuesday, September 8 to “Buy”. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Outperform” rating by Wedbush on Friday, September 23. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Market Perform” rating by Leerink Swann on Friday, January 29. Robert W. Baird maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Monday, October 23. Robert W. Baird has “Hold” rating and $4.0 target. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Hold” rating given on Wednesday, August 9 by Chardan Capital Markets.

Check-Cap Ltd. (NASDAQ:CHEK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: